WALTHAM, Mass. and WHITE PLAINS, N.Y., June 11, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) and March of Dimes today announced a strategic corporate partnership focused on a shared commitment to improve maternal health and birth outcomes, as well as to reduce health inequities. Through the partnership, AMAG will participate in the March of Dimes Prematurity Campaign Collaborative and support the expansion of the March of Dimes’ Supportive Pregnancy Care (SPC) model, an innovative group prenatal care program.
“AMAG’s commitment to support the health of patients and families encompasses far more than the therapies we offer to help moms and babies. We also focus on how we can help address broader unmet needs these families may be experiencing that impact their health and well-being,” said William Heiden, president and chief executive officer, AMAG Pharmaceuticals. “We are grateful for the opportunity to collaborate with March of Dimes to build on our existing efforts, and to advance both national and community-level initiatives aimed at giving expectant mothers and families the tools, resources and support they need to achieve healthy pregnancies and births.”
The March of Dimes Prematurity Campaign Collaborative aims to achieve health equity and demonstrated improvements in preterm birth outcomes. AMAG will contribute to the Collaborative in areas related to maternal and infant health equity, drawing on the company’s expertise in maternal health and standing collaborations with experts and clinicians to address this issue.
Additionally, AMAG’s support of the SPC program will create nine additional group prenatal care programs in site locations throughout the country. SPC seeks to improve health outcomes for mothers and babies by supplementing traditional medical care with social support, health education and skill-building in a group setting with a team of clinicians.
“The health of mothers and babies is critical to the overall health of our communities, and the work of our Prematurity Campaign Collaborative and Supportive Pregnancy Care program are focused on helping families and communities thrive,” said Stacey D. Stewart, President, March of Dimes. “With AMAG Pharmaceuticals, we are able to make even greater progress on improving health equity and access to comprehensive prenatal care, which can have a substantial impact on pregnancy and birth outcomes, as well as overall community health.”
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
ABOUT MARCH OF DIMES
March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every family can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we stand up for every mom and every baby. Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook and follow us on Instagram and Twitter.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to statements regarding beliefs that in collaborating with March of Dimes, AMAG will build on its existing efforts, advance national and community-level initiatives, contribute to the Collaborative in areas related to maternal and infant health equity, draw on its standing collaborations with experts and clinicians and create nine additional group prenatal care programs in site locations throughout the country; and beliefs that newborn stem cells have the potential to play a valuable role in the development of regenerative medicine are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, those identified in AMAG’s Securities and Exchange Commission (SEC) filings, including AMAG’s Annual Report on Form 10-K for the year ended December 31, 2017 and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.
AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals, Inc. Contact:
March of Dimes Contact:
AMAG Pharmaceuticals, Inc.